# Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate

Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate (EB/EPP/TP/TPP/TiC), sold under the brand names Estandron Prolongatum, Lynandron Prolongatum, and Mixogen, was an injectable combination medication of the estrogens estradiol benzoate (EB) and estradiol phenylpropionate (EPP) and the androgens/anabolic steroids testosterone propionate (TP), testosterone phenylpropionate (TPP), and testosterone isocaproate (TiC) which was used in menopausal hormone therapy for women. It was also used to suppress lactation in postpartum women.
The medication was provided in the form of 1 mL ampoules and 2 mL vials containing 1 mg/mL EB, 4 mg/mL EPP, 20 mg/mL TP, 40 mg/mL TPP, and 40 mg/mL TiC in an oil solution and was administered by intramuscular injection. EB/EPP/TP/TPP/TiC reportedly has a duration of about 14 days.
Estandron Prolongatum, Lynandron Prolongatum, and Mixogen were all introduced for medical use by 1956. Oral tablet products with the same brand names of Estandron, Lynandron, and Mixogen, containing ethinylestradiol and methyltestosterone, were marketed around the same time, and should not be confused with the injectable products. Estandron Prolongatum, Lynandron Prolongatum, and Mixogen remained marketed as late as the 1980s. EB/EPP/TP/TPP/TiC appears to no longer be marketed.
vte Androgen replacement therapy formulations and dosages used in women :
| Route | Medication | Major brand names | Form | Dosage |
| Oral | Testosterone undecanoate | Andriol, Jatenzo | Capsule | 40–80 mg 1x/1–2 days |
| Oral | Methyltestosterone | Metandren, Estratest | Tablet | 0.5–10 mg/day |
| Oral | Fluoxymesterone | Halotestin | Tablet | 1–2.5 mg 1x/1–2 days |
| Oral | Normethandrone$^a$ | Ginecoside | Tablet | 5 mg/day |
| Oral | Tibolone | Livial | Tablet | 1.25–2.5 mg/day |
| Oral | Prasterone (DHEA)$^b$ | – | Tablet | 10–100 mg/day |
| Sublingual | Methyltestosterone | Metandren | Tablet | 0.25 mg/day |
| Transdermal | Testosterone | Intrinsa | Patch | 150–300 μg/day |
| Transdermal | Testosterone | AndroGel | Gel, cream | 1–10 mg/day |
| Vaginal | Prasterone (DHEA) | Intrarosa | Insert | 6.5 mg/day |
| Injection | Testosterone propionate$^a$ | Testoviron | Oil solution | 25 mg 1x/1–2 weeks |
| Injection | Testosterone enanthate | Delatestryl, Primodian Depot | Oil solution | 25–100 mg 1x/4–6 weeks |
| Injection | Testosterone cypionate | Depo-Testosterone, Depo-Testadiol | Oil solution | 25–100 mg 1x/4–6 weeks |
| Injection | Testosterone isobutyrate$^a$ | Femandren M, Folivirin | Aqueous suspension | 25–50 mg 1x/4–6 weeks |
| Injection | Mixed testosterone esters | Climacteron$^a$ | Oil solution | 150 mg 1x/4–8 weeks |
| Injection | Mixed testosterone esters | Omnadren, Sustanon | Oil solution | 50–100 mg 1x/4–6 weeks |
| Injection | Nandrolone decanoate | Deca-Durabolin | Oil solution | 25–50 mg 1x/6–12 weeks |
| Injection | Prasterone enanthate$^a$ | Gynodian Depot | Oil solution | 200 mg 1x/4–6 weeks |
| Implant | Testosterone | Testopel | Pellet | 50–100 mg 1x/3–6 months |
| Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: $^a$ = Mostly discontinued or unavailable. $^b$ = Over-the-counter. Sources: See template. |||||